PCI High Potent Manufacturing
LB Bohle – 10.06.2025
Temax_Krautz

Current Edition

Current Edition

Subsection - CDMO

Examining how innovative technologies, integrated manufacturing approaches and AI are shaping manufacturing.

Continue reading

Subsection - Injectables

Exploring advances in injectable drug delivery and sterile manufacturing, designed to improve patient-centric delivery.

Continue reading

Subsection - Neurodegenerative Diseases

Exploring emerging approaches to neurodegenerative disease research and treatment.

Continue reading

Subsection - Nasal & Pulmonary

Highlighting how advances in nasal and pulmonary drug delivery, formulation, devices and analytics are enabling more complex therapies.

Continue reading

Advertisement

CPHI 2027
DDL 2026

Advertisement

Nipro August 26

Advertisement

Merxin March 2026

Advertisement

Aurisco 300×250

Advertisement

Lifecore Biomedical

NextPharma Expands OSD Capacity

As part of NextPharma’s ongoing strategy to continue to invest in its existing sites, in order to both increase capacity and to improve efficiency with modern state-of-the-art equipment, the European contract development and manufacturing organization (CDMO) recently completed a €15 million investment at its Goettingen, Germany site. The investment project, which was completed within 12 months, expands NextPharma’s existing capacity in manufacturing and packaging of oral solid dosage forms.

The project involved construction of a new 1,000 square meter building on two levels, with additional production facilities on the ground floor for mixing, compression, film coating and granulation. The investment has increased capacity at the site by 25%, equivalent to an increase in manufacturing and packaging capacity of approximately one billion tablets.

A high-performance packaging line for blister packs has been installed on the upper floor of the building, and another bottle packaging line will be added in the second quarter of 2021. The entire building is controlled with the most up-to-date building control and ventilation (HVAC) technology. The building and its facilities became operational in the third quarter of 2020.

“We are very happy to support both our existing and new customers’ product supply with this state-of-the-art additional capacity, which also represents a significant step in NextPharma’s growth strategy as a leading Europe-based CDMO,” said Peter Burema, chief executive officer, NextPharma. “Although today we celebrate the additional competitive capacity of solid dosage forms at our Goettingen site, we also continue to invest across all of our sites and capabilities, as we consider this to be imperative in order to meet the challenge of product supply within the pharmaceutical market, which has become even more visible during the Covid-19 crisis.”

NextPharma has a current footprint spanning five sites in Germany, one in France and one in Finland. It supplies products globally, with six of its seven sites FDA-approved. With expertise in solids, semi solids and non-sterile and sterile liquids, the company provides services from pharmaceutical development, clinical supplies, scale-up and process validation through to commercial manufacturing for a large range of dosage forms including tablets, capsules, granules, powders, pellets, gels, creams, sprays and syrups. Additionally, it provides a wide range of packaging solutions including blow-fill-seal, blisters, bottles, sachets, stick packs and tubes.

Advertisement

MedPharm 16/07

Advertisement

Biopharma group march 2026

Advertisement

Silgan March 2026

Advertisement

Terumo 06/26

Advertisement

Scott Pharma – 25.03.2025

Advertisement

Bespak

Advertisement

Solstice

Advertisement

Bachem skyscraper
Tjoapack
Aptar – 08/01/2026